Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements